Cover Image

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising...

Full description

Saved in:
Bibliographic Details
Main Authors: Luber, Birgit (Author) , Deplazes, Joëlle (Author) , Keller, Gisela (Author) , Walch, Axel (Author) , Rauser, Sandra (Author) , Eichmann, Martin (Author) , Langer, Rupert (Author) , Höfler, Heinz (Author) , Hegewisch-Becker, Susanna (Author) , Folprecht, Gunnar (Author) , Wöll, Ewald (Author) , Decker, Thomas (Author) , Endlicher, Esther (Author) , Lorenzen, Sylvie (Author) , Fend, Falko (Author) , Peschel, Christian (Author) , Lordick, Florian (Author)
Format: Article (Journal)
Language:English
Published: 2011
In: BMC cancer
Year: 2011, Volume: 11, Pages: 1-12
ISSN:1471-2407
DOI:10.1186/1471-2407-11-509
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-509
Verlag, lizenzpflichtig, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-509
Get full text
Author Notes:Birgit Luber, Joëlle Deplazes, Gisela Keller, Axel Walch, Sandra Rauser, Martin Eichmann, Rupert Langer, Heinz Höfler, Susanna Hegewisch-Becker, Gunnar Folprecht, Ewald Wöll, Thomas Decker, Esther Endlicher, Sylvie Lorenzen, Falko Fend, Christian Peschel and Florian Lordick
Description
Summary:The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising objective tumour response rate of 65% and a low mutation frequency of KRAS (3%). The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer treated with cetuximab combined with FUFOX.
Item Description:Gesehen am 10.11.2022
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-11-509

Similar Items